CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
NMPA OF CHINA GRANTS NDA APPROVAL TO TETANUS VACCINE

This announcement is made by CanSino Biologics Inc. (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that the National Medical Products Administration (the "**NMPA**") of China has granted new drug application (the "**NDA**") approval to the adsorbed tetanus vaccine (the "**Tetanus Vaccine**") developed by the Company.

Tetanus is an acute infectious disease caused by Clostridium tetani. Clostridium tetani produces an exotoxin known as tetanospasmin, which is the pathogenic agent of tetanus, causing generalized tonic contraction of skeletal muscle and paroxysmal spasms. Severe cases may develop complications such as laryngospasm, asphyxiation, pulmonary infections, and organ failure, with a mortality rate reaching 30%-50%. The mortality rate of tetanus approaches 100% without medical intervention, making it an extremely severe and potentially fatal disease.

The Company has developed the Tetanus Vaccine which is fermented with animal-free culture medium and is thus safer. Furthermore, stable industrial scale processes have been identified. This vaccine is primarily intended for non-neonatal tetanus prevention, which will enrich the Company's product pipeline and enhance its core competitiveness. The Phase III clinical data of the Tetanus Vaccine demonstrates that it can elicit a favorable immune response following vaccination. The antibody GMC (Geometric Mean Concentration) at 30 days post-vaccination was superior to that of the control vaccine, showing significant advantages over the control group, which indicates that the Tetanus Vaccine has good immunogenicity in the study population.

The launch of this product will enrich the Company's portfolio of commercialized products and expand its presence in the adult vaccine market. The Company has entered into an exclusive commercialization collaboration agreement with Grand Life Sciences Group for the Tetanus Vaccine. Pursuant to the agreement, the Company will grant Grand Life Sciences Group the exclusive right to promote the Tetanus Vaccine in Greater China following product approval, further expanding vaccine accessibility.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, August 20, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.